Literature DB >> 7024432

Inhibition of in vitro growth of Plasmodium falciparum by immune serum from monkeys.

J D Chulay, J D Haynes, C L Diggs.   

Abstract

Three owl monkeys that had been immunized against the Camp strain of Plasmodium falciparum by infection were treated with chloroquine and rechallenged with parasites. Immune serum caused a dose-dependent, time-dependent inhibition of in vitro parasite growth. Heat-inactivation eliminated nonspecific inhibition by normal monkey serum without diminishing immune inhibition. Purified IgG from immune serum inhibited parasite growth. Serum taken immediately before the second challenge did not inhibit growth in vitro at a 1:10 dilution, although the monkeys successfully resisted the in vivo challenge. However, immune sera from all three monkeys taken two to four weeks after in vivo challenges were inhibitory, but sometimes detection required 20% serum. Growth inhibition in vitro by 10% serum was a poor predictor of in vivo protective immunity. Undiluted blood containing higher antibody levels (which are boosted by challenge), combined with additional immune mechanisms, may explain the protection observed in vivo.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7024432     DOI: 10.1093/infdis/144.3.270

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  13 in total

1.  Epitope map and processing scheme for the 195,000-dalton surface glycoprotein of Plasmodium falciparum merozoites deduced from cloned overlapping segments of the gene.

Authors:  J A Lyon; R H Geller; J D Haynes; J D Chulay; J L Weber
Journal:  Proc Natl Acad Sci U S A       Date:  1986-05       Impact factor: 11.205

2.  Activation of monocytes and platelets by monoclonal antibodies or malaria-infected erythrocytes binding to the CD36 surface receptor in vitro.

Authors:  C F Ockenhouse; C Magowan; J D Chulay
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

3.  Analysis of inhibitory epitopes in the Plasmodium falciparum rhoptry protein RAP-1 including identification of a second inhibitory epitope.

Authors:  R F Howard; K C Jacobson; E Rickel; J Thurman
Journal:  Infect Immun       Date:  1998-01       Impact factor: 3.441

4.  Serotypes of Plasmodium falciparum defined by immune serum inhibition of in vitro growth.

Authors:  J D Chulay; J D Haynes; C L Diggs
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

5.  Cooperation between antibodies and monocytes that inhibit in vitro proliferation of Plasmodium falciparum.

Authors:  S Khusmith; P Druilhe
Journal:  Infect Immun       Date:  1983-07       Impact factor: 3.441

6.  Serum containing tumor necrosis factor is cytotoxic for the human malaria parasite Plasmodium falciparum.

Authors:  C G Haidaris; J D Haynes; M S Meltzer; A C Allison
Journal:  Infect Immun       Date:  1983-10       Impact factor: 3.441

7.  Association between human serum-induced crisis forms in cultured Plasmodium falciparum and clinical immunity to malaria in Sudan.

Authors:  J B Jensen; M T Boland; J S Allan; J M Carlin; J A Vande Waa; A A Divo; M A Akood
Journal:  Infect Immun       Date:  1983-09       Impact factor: 3.441

Review 8.  Malaria vaccines.

Authors:  A A Holder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

9.  Primary structure of the 175K Plasmodium falciparum erythrocyte binding antigen and identification of a peptide which elicits antibodies that inhibit malaria merozoite invasion.

Authors:  B K Sim; P A Orlandi; J D Haynes; F W Klotz; J M Carter; D Camus; M E Zegans; J D Chulay
Journal:  J Cell Biol       Date:  1990-11       Impact factor: 10.539

10.  A malaria invasion receptor, the 175-kilodalton erythrocyte binding antigen of Plasmodium falciparum recognizes the terminal Neu5Ac(alpha 2-3)Gal- sequences of glycophorin A.

Authors:  P A Orlandi; F W Klotz; J D Haynes
Journal:  J Cell Biol       Date:  1992-02       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.